121 related articles for article (PubMed ID: 37953500)
1. Population Dose-Response-Time Analysis of Itch Reduction and Patient-Reported Tolerability Supports Phase III Dose Selection for Linerixibat.
Carreño F; Karatza E; Mehta R; Collins J; Austin D; Swift B
Clin Pharmacol Ther; 2024 Feb; 115(2):288-298. PubMed ID: 37953500
[TBL] [Abstract][Full Text] [Related]
2. GLIMMER: A Randomized Phase 2b Dose-Ranging Trial of Linerixibat in Primary Biliary Cholangitis Patients With Pruritus.
Levy C; Kendrick S; Bowlus CL; Tanaka A; Jones D; Kremer AE; Mayo MJ; Haque N; von Maltzahn R; Allinder M; Swift B; McLaughlin MM; Hirschfield GM;
Clin Gastroenterol Hepatol; 2023 Jul; 21(7):1902-1912.e13. PubMed ID: 36343847
[TBL] [Abstract][Full Text] [Related]
3. Relationship between pruritus and sleep in participants with primary biliary cholangitis in the Phase 2b GLIMMER trial.
von Maltzahn R; Mayo MJ; Smith HT; Thompson A; Das S; de Souza AR; Lisi E; Levy C; McLaughlin MM; Jones D
J Patient Rep Outcomes; 2024 Jun; 8(1):60. PubMed ID: 38862718
[TBL] [Abstract][Full Text] [Related]
4. Japanese subgroup analysis of GLIMMER: A global Phase IIb study of linerixibat for the treatment of cholestatic pruritus in patients with primary biliary cholangitis.
Tanaka A; Atsukawa M; Tsuji K; Notsumata K; Suyama A; Ito H; Das S; von Maltzahn R; McLaughlin MM
Hepatol Res; 2023 Jul; 53(7):629-640. PubMed ID: 36852705
[TBL] [Abstract][Full Text] [Related]
5. Serum bile acid change correlates with improvement in pruritus in patients with primary biliary cholangitis receiving linerixibat.
Karatza E; Swift B; Carreño F; Mukherjee S; Casillas L; Lennie J; Fettiplace J; McLaughlin MM; Kremer AE
Liver Int; 2024 May; ():. PubMed ID: 38780109
[TBL] [Abstract][Full Text] [Related]
6. Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study.
Hegade VS; Kendrick SF; Dobbins RL; Miller SR; Thompson D; Richards D; Storey J; Dukes GE; Corrigan M; Oude Elferink RP; Beuers U; Hirschfield GM; Jones DE
Lancet; 2017 Mar; 389(10074):1114-1123. PubMed ID: 28187915
[TBL] [Abstract][Full Text] [Related]
7. BAT117213: Ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trial.
Hegade VS; Kendrick SF; Dobbins RL; Miller SR; Richards D; Storey J; Dukes G; Gilchrist K; Vallow S; Alexander GJ; Corrigan M; Hirschfield GM; Jones DE
BMC Gastroenterol; 2016 Jul; 16(1):71. PubMed ID: 27431238
[TBL] [Abstract][Full Text] [Related]
8. Fibrates for Itch (FITCH) in Fibrosing Cholangiopathies: A Double-Blind, Randomized, Placebo-Controlled Trial.
de Vries E; Bolier R; Goet J; Parés A; Verbeek J; de Vree M; Drenth J; van Erpecum K; van Nieuwkerk K; van der Heide F; Mostafavi N; Helder J; Ponsioen C; Oude Elferink R; van Buuren H; Beuers U;
Gastroenterology; 2021 Feb; 160(3):734-743.e6. PubMed ID: 33031833
[TBL] [Abstract][Full Text] [Related]
9. Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis.
Kremer AE; Mayo MJ; Hirschfield G; Levy C; Bowlus CL; Jones DE; Steinberg A; McWherter CA; Choi YJ
Liver Int; 2022 Jan; 42(1):112-123. PubMed ID: 34403559
[TBL] [Abstract][Full Text] [Related]
10. Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis.
Schramm C; Wedemeyer H; Mason A; Hirschfield GM; Levy C; Kowdley KV; Milkiewicz P; Janczewska E; Malova ES; Sanni J; Koo P; Chen J; Choudhury S; Klickstein LB; Badman MK; Jones D
JHEP Rep; 2022 Nov; 4(11):100544. PubMed ID: 36267872
[TBL] [Abstract][Full Text] [Related]
11. Pilot study with IBAT inhibitor A4250 for the treatment of cholestatic pruritus in primary biliary cholangitis.
Al-Dury S; Wahlström A; Wahlin S; Langedijk J; Elferink RO; Ståhlman M; Marschall HU
Sci Rep; 2018 Apr; 8(1):6658. PubMed ID: 29704003
[TBL] [Abstract][Full Text] [Related]
12. GLIMMER Trial-A Randomized, Double-Blind, Placebo-Controlled Study of Linerixibat, an Inhibitor of the Ileal Bile Acid Transporter, in the Treatment of Cholestatic Pruritus in Primary Biliary Cholangitis.
Gastroenterol Hepatol (N Y); 2021 Feb; 17(2 Suppl 3):11-12. PubMed ID: 34135716
[No Abstract] [Full Text] [Related]
13. Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial.
Ständer S; Kwatra SG; Silverberg JI; Simpson EL; Thyssen JP; Yosipovitch G; Zhang F; Cameron MC; Cella RR; Valdez H; DiBonaventura M; Feeney C
Am J Clin Dermatol; 2023 Jan; 24(1):97-107. PubMed ID: 36512175
[TBL] [Abstract][Full Text] [Related]
14. Fibrates for the treatment of cholestatic itch (FITCH): study protocol for a randomized controlled trial.
Bolier R; de Vries ES; Parés A; Helder J; Kemper EM; Zwinderman K; Elferink RPO; Beuers U;
Trials; 2017 May; 18(1):230. PubMed ID: 28535810
[TBL] [Abstract][Full Text] [Related]
15. Interventions for pityriasis rosea.
Contreras-Ruiz J; Peternel S; Jiménez Gutiérrez C; Culav-Koscak I; Reveiz L; Silbermann-Reynoso ML
Cochrane Database Syst Rev; 2019 Oct; 2019(10):. PubMed ID: 31684696
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and ADME Characterization of Intravenous and Oral [
Zamek-Gliszczynski MJ; Kenworthy D; Bershas DA; Sanghvi M; Pereira AI; Mudunuru J; Crossman L; Pirhalla JL; Thorpe KM; Dennison JMTJ; McLaughlin MM; Allinder M; Swift B; O'Connor-Semmes RL; Young GC
Drug Metab Dispos; 2021 Dec; 49(12):1109-1117. PubMed ID: 34625435
[TBL] [Abstract][Full Text] [Related]
17. A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus.
Fishbane S; Jamal A; Munera C; Wen W; Menzaghi F;
N Engl J Med; 2020 Jan; 382(3):222-232. PubMed ID: 31702883
[TBL] [Abstract][Full Text] [Related]
18. Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis.
Yosipovitch G; Reaney M; Mastey V; Eckert L; Abbé A; Nelson L; Clark M; Williams N; Chen Z; Ardeleanu M; Akinlade B; Graham NMH; Pirozzi G; Staudinger H; Plaum S; Radin A; Gadkari A
Br J Dermatol; 2019 Oct; 181(4):761-769. PubMed ID: 30729499
[TBL] [Abstract][Full Text] [Related]
19. Effects of odevixibat on pruritus and bile acids in children with cholestatic liver disease: Phase 2 study.
Baumann U; Sturm E; Lacaille F; Gonzalès E; Arnell H; Fischler B; Jørgensen MH; Thompson RJ; Mattsson JP; Ekelund M; Lindström E; Gillberg PG; Torfgård K; Soni PN
Clin Res Hepatol Gastroenterol; 2021 Sep; 45(5):101751. PubMed ID: 34182185
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Difelikefalin in Japanese Patients With Moderate to Severe Pruritus Receiving Hemodialysis: A Randomized Clinical Trial.
Narita I; Tsubakihara Y; Uchiyama T; Okamura S; Oya N; Takahashi N; Gejyo F;
JAMA Netw Open; 2022 May; 5(5):e2210339. PubMed ID: 35511180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
